NEOSTIGMINE METHYLSULFATE Drug Patent Profile

When do Neostigmine Methylsulfate patents expire, and what generic alternatives are available?

Neostigmine Methylsulfate is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Avet Lifesciences, Be Pharms, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Meitheal, Ph Health, Regcon Holdings, Sagent Pharms Inc, and Umedica. and is included in nineteen NDAs.

The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neostigmine Methylsulfate

A generic version of NEOSTIGMINE METHYLSULFATE was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8^th, 2015.

Summary for NEOSTIGMINE METHYLSULFATE

US Patents:	0
Applicants:	17
NDAs:	19
Finished Product Suppliers / Packagers:	23
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	9
Patent Applications:	1,032
Drug Prices:	Drug price information for NEOSTIGMINE METHYLSULFATE
What excipients (inactive ingredients) are in NEOSTIGMINE METHYLSULFATE?	NEOSTIGMINE METHYLSULFATE excipients list
DailyMed Link:	NEOSTIGMINE METHYLSULFATE at DailyMed

See drug prices for NEOSTIGMINE METHYLSULFATE

Recent Clinical Trials for NEOSTIGMINE METHYLSULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	N/A
Kasr El Aini Hospital	Phase 4
Alexandria University	Phase 4

See all NEOSTIGMINE METHYLSULFATE clinical trials

Pharmacology for NEOSTIGMINE METHYLSULFATE

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Medical Subject Heading (MeSH) Categories for NEOSTIGMINE METHYLSULFATE

Cholinesterase Inhibitors

Parasympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for NEOSTIGMINE METHYLSULFATE

N07AA	Anticholinesterases
N07A	PARASYMPATHOMIMETICS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

S01EB	Parasympathomimetics
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for NEOSTIGMINE METHYLSULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Regcon Holdings	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	210652-001	Oct 1, 2021	AP	RX	No	No
Meitheal	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	212804-001	Apr 5, 2021	AP	RX	No	No
Regcon Holdings	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	210652-002	Oct 1, 2021	AP	RX	No	No

NEOSTIGMINE METHYLSULFATE Market Analysis and Financial Projection

Last updated: February 12, 2026

Market Dynamics and Financial Trajectory for Neostigmine Methylsulfate

Neostigmine methylsulfate, a reversible cholinesterase inhibitor, is mainly used to reverse neuromuscular blockade following surgery, diagnose neuromuscular disorders, and treat conditions like myasthenia gravis. Its market relevance depends on clinical demand, regulatory status, and competitive landscape.

---

Current Market Environment

Demand Drivers:

• Surgical Procedures: The increase in outpatient surgeries elevates the need for neuromuscular blockade reversal agents like neostigmine.
• Myasthenia Gravis and Other Disorders: Rising prevalence of neuromuscular disorders sustains demand.
• Diagnostic Applications: Use in neuromuscular transmission testing maintains niche usage.

Supply Factors:

• Manufacturers: Major players include Fresenius Kabi, Sagent Pharmaceuticals, and local generic producers.
• Manufacturing Challenges: Complex synthesis processes and need for sterile formulations influence production costs and supply stability.

Regulatory Considerations:

• Approved by FDA, EMA, and other agencies with established safety profiles.
• Generic versions dominate markets in North America, Europe, and parts of Asia.

Competitive Landscape:

• Limited number of branded versus numerous generic suppliers.
• Alternative agents like edrophonium exist for diagnostic purposes but not as primary therapeutics.

---

Market Size and Revenue Projections

Global Market Valuation:

• Estimated to be valued at approximately $150 million in 2022 (market research reports[1]).
• Compound annual growth rate (CAGR): Projected between 2% and 4% over the next five years, driven by surgical volume increases.

Regional Insights:

• North America accounts for about 45% of the global market, aided by higher surgical rates.
• Europe and Asia-Pacific follow, with Asia-Pacific expected to experience higher CAGR (around 4%) due to expanding healthcare infrastructure and surgical procedures.

---

Revenue and Pricing Trends

• Price per vial: Ranges from $2 to $10, depending on concentration, formulation, and manufacturer.
• Market penetration of generics suppresses prices but stabilizes volume sales.

Pricing Dynamics:

• Patent expiration in early 2000s led to a surge in generic availability.
• Price competition limits revenue growth potential for branded versions.

Sales Outlook:

• Market growth primarily driven by volume increases rather than price hikes.
• Stable demand expected barring major regulatory or clinical shifts.

---

Future Market Indicators

Technological Innovation:

• No significant new formulations or delivery methods for neostigmine methylsulfate.
• Similar agents with improved profiles may vie for market share.

Regulatory and Policy Environment:

• Governments emphasize surgical and neuromuscular disorder treatment access.
• Cost-containment policies may hinder price increases.

Pipeline and Competition:

• No notable pipeline candidates or reformulations are under development.
• Market likely to remain dominated by existing generics.

---

Financial Trajectory Summary

Metric	2022 Estimate	2027 Projection
Market Valuation	$150 million	~$180 million to $200 million
CAGR	3%	3-4%
Regional Growth Factors	Mature markets slow; emerging markets grow	Accelerated growth in Asia-Pacific
Price per Vial	$2 - $10	Stable or slightly decreased due to generics
Manufacturing Costs	Stable, moderate increase	Slight decrease with process optimization

Overall Outlook: Modest growth, primarily volume-driven, with limited opportunities for premium pricing or product differentiation.

---

Key Takeaways

• The market for neostigmine methylsulfate remains stable, primarily driven by surgical and neuromuscular disorder treatment needs.
• Market size projected to grow at 3-4% annually until 2027, reaching an estimated $180-$200 million globally.
• Generic market shares dominate, constraining pricing power.
• No significant innovation or pipeline activity exists for neostigmine methylsulfate, limiting growth to volume increases.
• Growth prospects are better in emerging markets with expanding healthcare infrastructure.

---

FAQs

1. What factors influence the pricing of neostigmine methylsulfate?
Pricing is impacted by generic competition, manufacturing costs, and market demand. Patent expirations led to price stabilization and lower costs.

2. Which regions hold the largest market share?
North America accounts for roughly 45%, followed by Europe and Asia-Pacific, with higher growth forecasted in Asia-Pacific.

3. What are the main clinical applications for neostigmine methylsulfate?
Reversal of neuromuscular blockade post-surgery, diagnosis of neuromuscular disorders like myasthenia gravis, and neuromuscular transmission testing.

4. Are there any emerging competitors or new formulations?
No significant pipeline or reformulation efforts are currently public, and the market relies on existing formulations.

5. How do regulatory policies affect future demand?
Regulations favoring access to surgical and neuromuscular treatments support ongoing demand, but cost-containment measures may limit pricing increases or new product approvals.

---

References

[1] Market research reports on neuromuscular agents, 2022.